Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q3 FY26 results · Oct–Dec 2025
Solara Active Pharma Sciences reported revenue from operations of ₹349.00 crore (up 16.2% from Q3 FY25) and net loss of ₹17.43 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 349.00 | 300.31 | +16.2% | 313.54 | +11.3% |
| Other income | 0.00 | 1.49 | −100.0% | 0.49 | −100.0% |
| Total income | 349.00 | 301.80 | +15.6% | 314.03 | +11.1% |
| Profit before tax | (17.43) | 8.09 | Turned loss | (10.10) | Loss widened |
| Net profit for the period | (17.43) | 8.09 | Turned loss | (10.10) | Loss widened |
| EPS, basic (₹) | (3.98) | 2.03 | not comparable | (2.36) | Loss widened |
| Net margin (%) | -5.0 | 2.7 | -3.2 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 349.00 | 300.31 | +16.2% | 313.54 | +11.3% |
| Other income | 0.00 | 1.49 | −100.0% | 0.49 | −100.0% |
| Total income | 349.00 | 301.80 | +15.6% | 314.03 | +11.1% |
| Profit before tax | (17.42) | 8.10 | Turned loss | (10.08) | Loss widened |
| Net profit for the period | (17.42) | 8.10 | Turned loss | (10.08) | Loss widened |
| EPS, basic (₹) | (3.97) | 2.47 | not comparable | (2.36) | Loss widened |
| Net margin (%) | -5.0 | 2.7 | -3.2 |
Consolidated
- Filed with BSE
- 06 Feb 2026, 17:39 IST
- Board meeting
- 06 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2026, 17:39 IST
- Board meeting
- 06 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE